Search

Your search keyword '"Huang, S.-F."' showing total 385 results
Start Over Author "Huang, S.-F."
385 results on '"Huang, S.-F."'

4. EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis

Author

Shih, C-H, Chang, Y-J, Huang, W-C, Jang, T-H, Kung, H-J, Wang, W-C, Yang, M-H, Lin, M-C, Huang, S-F, Chou, S-W, Chang, E, Chiu, H, Shieh, T-Y, Chen, Y-J, Wang, L-H, and Chen, L

Subjects
Orphan Drug, Lung, Cancer, Genetics, Dental/Oral and Craniofacial Disease, Lung Cancer, Rare Diseases, 2.1 Biological and endogenous factors, Aetiology, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Animals, Biomarkers, Tumor, Carcinoma, Squamous Cell, Cell Line, Tumor, Cell Proliferation, Chemokine CXCL1, Down-Regulation, Enhancer of Zeste Homolog 2 Protein, ErbB Receptors, Gene Expression Regulation, Neoplastic, Histones, Humans, Lung Neoplasms, Male, Methylation, Mice, Molecular Targeted Therapy, Mouth Neoplasms, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, STAT1 Transcription Factor, Up-Regulation, Xenograft Model Antitumor Assays, Zinc Finger Protein GLI1, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Current anti-epidermal growth factor receptor (EGFR) therapy for oral cancer does not provide satisfactory efficacy due to drug resistance or reduced EGFR level. As an alternative candidate target for therapy, here we identified an oncogene, ROS1, as an important driver for oral squamous cell carcinoma (OSCC) metastasis. Among tumors from 188 oral cancer patients, upregulated ROS1 expression strongly correlated with metastasis to lung and lymph nodes. Mechanistic studies uncover that the activated ROS1 results from highly expressed ROS1 gene instead of gene rearrangement, a phenomenon distinct from other cancers. Our data further reveal a novel mechanism that reduced histone methyltransferase EZH2 leads to a lower trimethylation of histone H3 lysine 27 suppressive modification, relaxes chromatin, and promotes the accessibility of the transcription factor STAT1 to the enhancer and the intron regions of ROS1 target genes, CXCL1 and GLI1, for upregulating their expressions. Down-regulation of ROS1 in highly invasive OSCC cells, nevertheless, reduces cell proliferation and inhibits metastasis to lung in the tail-vein injection and the oral cavity xenograft models. Our findings highlight ROS1 as a candidate biomarker and therapeutic target for OSCC. Finally, we demonstrate that co-targeting of ROS1 and EGFR could potentially offer an effective oral cancer therapy.

Published
2017

10. Red cell distribution width as a predictor of mortality after hip fracture: a systematic review and meta-analysis.

Author

ZHU, X.-F., WENG, H.-Y., and HUANG, S.-F.

Abstract

OBJECTIVE: This review examined the association between red cell distribution width (RDW) and mortality after hip fracture. MATERIALS AND METHODS: PubMed, CENTRAL, Scopus, Web of Science, and Embase were searched up to 10th January 2023 for studies comparing mortality after hip fracture based on RDW. All cut-offs of RDW were accepted. Crude and adjusted mortality ratios were pooled separately. RESULTS: Nine studies with 5,274 patients were eligible. Meta-analysis of eight studies reporting crude mortality rates showed that patients with high RDW had a significantly higher risk of mortality than those with low RDW (RR: 2.81 95% CI: 2.05, 3.86 I2=82%). The results did not change in significance on subgroup analyses based on study location, sample size, the cut-off of RDW, and follow-up. Four studies reported adjusted mortality rates. Analysis of the same showed that high RDW was an independent predictor of mortality in hip fracture patients (HR: 3.14 95% CI: 1.38, 7.14 I2=95%). CONCLUSIONS: Within the limitations of the review, RDW was found to be an indicator of mortality in hip fracture patients. High RDW was significantly associated with increased mortality despite different cut-offs among studies. Further research is needed to generate more rigorous evidence. [ABSTRACT FROM AUTHOR]

Published
2023

16. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer

Author

Chen, J. S., Hsu, C., Chiang, N. J., Tsai, C. S., Tsou, H. H., Huang, S. F., Bai, L. Y., Chang, I. C., Shiah, H. S., Ho, C. L., Yen, C. J., Lee, K. D., Chiu, C. F., Rau, K. M., Yu, M. S., Yang, Y., Hsieh, R. K., Chang, J. Y., Shan, Y. S., Chao, Y., Chen, L. T., Shen, Wen-Chi, Hsu, Hung-Chih, Hsu, Chih-Hung, Shen, Ying-Chun, Wang, Tsang-En, Li, Chung-Pin, Chen, Ming-Huang, Kao, Wei-Yao, Chang, Ping-Ying, Wu, Cheng-Chung, Teng, Chien-Lin, Lu, Chang-Hsien, Lin, Shyh-Jer, Wang, Being-Whey, Chen, Yen-Yang, Chin, Yung-Hsin, Chung, Tsai-Rong, Yu, Wei-Lan, Lee, Mei-Hua, Lin, Ling-Fang, Lin, Pei-Chyi, Wu, Ya-Ling, Wang, Hui-Ling, Lu, Li-Ju, Chen, Shiang-Yi, Wu, Chih-Chu, and Wei, Te-Chih

Published
2015
Full Text
View/download PDF

21. Incidence and management of metabolic acidosis with sodium bicarbonate in the ICU: An international observational study.

Author

Tsai H.-E., Nichol A., Bellomo R., Deane A.M., El-Khawas K., Thummaporn N., Serpa Neto A., Bergin H., Short-Burchell R., Chen C.-M., Cheng K.-H., Cheng K.-C., Chia C., Chiang F.-F., Chou N.-K., Fazio T., Fu P.-K., Ge V., Hayashi Y., Roodenburg O., Saito S., Santamaria J.D., Shehabi Y., Tanaka A., Tiruvoipati R., Udy A.A., Wang A.-Y., Wang C.-Y., Yeh Y.-C., Yu C.-J., Yuan K.-C., Fujii T., Holmes J., Hu T.-Y., Huang S.-F., Iguchi N., Jones S.L., Karumai T., Katayama S., Ku S.-C., Lai C.-L., Lee B.-J., Liaw W.-J., Ong C.T.W., Paxton L., Peppin C., Tsai H.-E., Nichol A., Bellomo R., Deane A.M., El-Khawas K., Thummaporn N., Serpa Neto A., Bergin H., Short-Burchell R., Chen C.-M., Cheng K.-H., Cheng K.-C., Chia C., Chiang F.-F., Chou N.-K., Fazio T., Fu P.-K., Ge V., Hayashi Y., Roodenburg O., Saito S., Santamaria J.D., Shehabi Y., Tanaka A., Tiruvoipati R., Udy A.A., Wang A.-Y., Wang C.-Y., Yeh Y.-C., Yu C.-J., Yuan K.-C., Fujii T., Holmes J., Hu T.-Y., Huang S.-F., Iguchi N., Jones S.L., Karumai T., Katayama S., Ku S.-C., Lai C.-L., Lee B.-J., Liaw W.-J., Ong C.T.W., Paxton L., and Peppin C.

Abstract

BACKGROUND: Metabolic acidosis is a major complication of critical illness. However, its current epidemiology and its treatment with sodium bicarbonate given to correct metabolic acidosis in the ICU are poorly understood. METHOD(S): This was an international retrospective observational study in 18 ICUs in Australia, Japan, and Taiwan. Adult patients were consecutively screened, and those with early metabolic acidosis (pH<7.3 and a Base Excess<-4 mEq/L, within 24-h of ICU admission) were included. Screening continued until 10 patients who received and 10 patients who did not receive sodium bicarbonate in the first 24 h (early bicarbonate therapy) were included at each site. The primary outcome was ICU mortality, and the association between sodium bicarbonate and the clinical outcomes were assessed using regression analysis with generalized linear mixed model. RESULT(S): We screened 9437 patients. Of these, 1292 had early metabolic acidosis (14.0%). Early sodium bicarbonate was given to 18.0% (233/1292) of these patients. Dosing, physiological, and clinical outcome data were assessed in 360 patients. The median dose of sodium bicarbonate in the first 24 h was 110 mmol, which was not correlated with bodyweight or the severity of metabolic acidosis. Patients who received early sodium bicarbonate had higher APACHE III scores, lower pH, lower base excess, lower PaCO2, and a higher lactate and received higher doses of vasopressors. After adjusting for confounders, the early administration of sodium bicarbonate was associated with an adjusted odds ratio (aOR) of 0.85 (95% CI, 0.44 to 1.62) for ICU mortality. In patients with vasopressor dependency, early sodium bicarbonate was associated with higher mean arterial pressure at 6 h and an aOR of 0.52 (95% CI, 0.22 to 1.19) for ICU mortality. CONCLUSION(S): Early metabolic acidosis is common in critically ill patients. Early sodium bicarbonate is administered by clinicians to more severely ill patients but without correction fo

Published
2021

22. Incidence and management of metabolic acidosis with sodium bicarbonate in the ICU: An international observational study.

Author

Udy A.A., Nichol A., Bellomo R., Deane A.M., El-Khawas K., Thummaporn N., Serpa Neto A., Bergin H., Short-Burchell R., Chen C.-M., Cheng K.-H., Cheng K.-C., Chia C., Chiang F.-F., Chou N.-K., Fazio T., Fu P.-K., Ge V., Hayashi Y., Holmes J., Hu T.-Y., Huang S.-F., Iguchi N., Jones S.L., Karumai T., Katayama S., Ku S.-C., Lai C.-L., Lee B.-J., Liaw W.-J., Ong C.T.W., Paxton L., Peppin C., Roodenburg O., Saito S., Santamaria J.D., Shehabi Y., Tanaka A., Tiruvoipati R., Tsai H.-E., Wang A.-Y., Wang C.-Y., Yeh Y.-C., Yu C.-J., Yuan K.-C., Fujii T., Neto A.S., Bone A., Jones S., Santamaria J., Clavarino L.-A., Ong C., Hirth S., Shima J., Takatsudo F., Suzuki K., Udy A.A., Nichol A., Bellomo R., Deane A.M., El-Khawas K., Thummaporn N., Serpa Neto A., Bergin H., Short-Burchell R., Chen C.-M., Cheng K.-H., Cheng K.-C., Chia C., Chiang F.-F., Chou N.-K., Fazio T., Fu P.-K., Ge V., Hayashi Y., Holmes J., Hu T.-Y., Huang S.-F., Iguchi N., Jones S.L., Karumai T., Katayama S., Ku S.-C., Lai C.-L., Lee B.-J., Liaw W.-J., Ong C.T.W., Paxton L., Peppin C., Roodenburg O., Saito S., Santamaria J.D., Shehabi Y., Tanaka A., Tiruvoipati R., Tsai H.-E., Wang A.-Y., Wang C.-Y., Yeh Y.-C., Yu C.-J., Yuan K.-C., Fujii T., Neto A.S., Bone A., Jones S., Santamaria J., Clavarino L.-A., Ong C., Hirth S., Shima J., Takatsudo F., and Suzuki K.

Abstract

Background: Metabolic acidosis is a major complication of critical illness. However, its current epidemiology and its treatment with sodium bicarbonate given to correct metabolic acidosis in the ICU are poorly understood. Method(s): This was an international retrospective observational study in 18 ICUs in Australia, Japan, and Taiwan. Adult patients were consecutively screened, and those with early metabolic acidosis (pH < 7.3 and a Base Excess < -4 mEq/L, within 24-h of ICU admission) were included. Screening continued until 10 patients who received and 10 patients who did not receive sodium bicarbonate in the first 24 h (early bicarbonate therapy) were included at each site. The primary outcome was ICU mortality, and the association between sodium bicarbonate and the clinical outcomes were assessed using regression analysis with generalized linear mixed model. Result(s): We screened 9437 patients. Of these, 1292 had early metabolic acidosis (14.0%). Early sodium bicarbonate was given to 18.0% (233/1292) of these patients. Dosing, physiological, and clinical outcome data were assessed in 360 patients. The median dose of sodium bicarbonate in the first 24 h was 110 mmol, which was not correlated with bodyweight or the severity of metabolic acidosis. Patients who received early sodium bicarbonate had higher APACHE III scores, lower pH, lower base excess, lower PaCO2, and a higher lactate and received higher doses of vasopressors. After adjusting for confounders, the early administration of sodium bicarbonate was associated with an adjusted odds ratio (aOR) of 0.85 (95% CI, 0.44 to 1.62) for ICU mortality. In patients with vasopressor dependency, early sodium bicarbonate was associated with higher mean arterial pressure at 6 h and an aOR of 0.52 (95% CI, 0.22 to 1.19) for ICU mortality. Conclusion(s): Early metabolic acidosis is common in critically ill patients. Early sodium bicarbonate is administered by clinicians to more severely ill patients but without correctio

Published
2021

23. Incidence and management of metabolic acidosis with sodium bicarbonate in the ICU: An international observational study

Author

Fujii, T, Udy, AA, Nichol, A, Bellomo, R, Deane, AM, El-Khawas, K, Thummaporn, N, Serpa Neto, A, Bergin, H, Short-Burchell, R, Chen, C-M, Cheng, K-H, Cheng, K-C, Chia, C, Chiang, F-F, Chou, N-K, Fazio, T, Fu, P-K, Ge, V, Hayashi, Y, Holmes, J, Hu, T-Y, Huang, S-F, Iguchi, N, Jones, SL, Karumai, T, Katayama, S, Ku, S-C, Lai, C-L, Lee, B-J, Liaw, W-J, Ong, CTW, Paxton, L, Peppin, C, Roodenburg, O, Saito, S, Santamaria, JD, Shehabi, Y, Tanaka, A, Tiruvoipati, R, Tsai, H-E, Wang, A-Y, Wang, C-Y, Yeh, Y-C, Yu, C-J, Yuan, K-C, Fujii, T, Udy, AA, Nichol, A, Bellomo, R, Deane, AM, El-Khawas, K, Thummaporn, N, Serpa Neto, A, Bergin, H, Short-Burchell, R, Chen, C-M, Cheng, K-H, Cheng, K-C, Chia, C, Chiang, F-F, Chou, N-K, Fazio, T, Fu, P-K, Ge, V, Hayashi, Y, Holmes, J, Hu, T-Y, Huang, S-F, Iguchi, N, Jones, SL, Karumai, T, Katayama, S, Ku, S-C, Lai, C-L, Lee, B-J, Liaw, W-J, Ong, CTW, Paxton, L, Peppin, C, Roodenburg, O, Saito, S, Santamaria, JD, Shehabi, Y, Tanaka, A, Tiruvoipati, R, Tsai, H-E, Wang, A-Y, Wang, C-Y, Yeh, Y-C, Yu, C-J, and Yuan, K-C

Abstract

BACKGROUND: Metabolic acidosis is a major complication of critical illness. However, its current epidemiology and its treatment with sodium bicarbonate given to correct metabolic acidosis in the ICU are poorly understood. METHOD: This was an international retrospective observational study in 18 ICUs in Australia, Japan, and Taiwan. Adult patients were consecutively screened, and those with early metabolic acidosis (pH < 7.3 and a Base Excess < -4 mEq/L, within 24-h of ICU admission) were included. Screening continued until 10 patients who received and 10 patients who did not receive sodium bicarbonate in the first 24 h (early bicarbonate therapy) were included at each site. The primary outcome was ICU mortality, and the association between sodium bicarbonate and the clinical outcomes were assessed using regression analysis with generalized linear mixed model. RESULTS: We screened 9437 patients. Of these, 1292 had early metabolic acidosis (14.0%). Early sodium bicarbonate was given to 18.0% (233/1292) of these patients. Dosing, physiological, and clinical outcome data were assessed in 360 patients. The median dose of sodium bicarbonate in the first 24 h was 110 mmol, which was not correlated with bodyweight or the severity of metabolic acidosis. Patients who received early sodium bicarbonate had higher APACHE III scores, lower pH, lower base excess, lower PaCO2, and a higher lactate and received higher doses of vasopressors. After adjusting for confounders, the early administration of sodium bicarbonate was associated with an adjusted odds ratio (aOR) of 0.85 (95% CI, 0.44 to 1.62) for ICU mortality. In patients with vasopressor dependency, early sodium bicarbonate was associated with higher mean arterial pressure at 6 h and an aOR of 0.52 (95% CI, 0.22 to 1.19) for ICU mortality. CONCLUSIONS: Early metabolic acidosis is common in critically ill patients. Early sodium bicarbonate is administered by clinicians to more severely ill patients but without correction for w

Published
2021

44. MiR-23∼27∼24-mediated control of humoral immunity reveals a TOX-driven regulatory circuit in follicular helper T cell differentiation

Author

Wu, C-J, Cho, S, Huang, H-Y, Lu, C-H, Russ, J, Cruz, LO, da Cunha, FF, Chen, M-C, Lin, L-L, Warner, LM, Liao, H-K, Utzschneider, DT, Quon, S, Berner, J, Saraiva Camara, NO, Zehn, D, Belmonte, JCI, Chen, L-C, Huang, S-F, Kuo, M-L, Lu, L-F, Wu, C-J, Cho, S, Huang, H-Y, Lu, C-H, Russ, J, Cruz, LO, da Cunha, FF, Chen, M-C, Lin, L-L, Warner, LM, Liao, H-K, Utzschneider, DT, Quon, S, Berner, J, Saraiva Camara, NO, Zehn, D, Belmonte, JCI, Chen, L-C, Huang, S-F, Kuo, M-L, and Lu, L-F

Abstract

Follicular helper T (TFH) cells are essential for generating protective humoral immunity. To date, microRNAs (miRNAs) have emerged as important players in regulating TFH cell biology. Here, we show that loss of miR-23~27~24 clusters in T cells resulted in elevated TFH cell frequencies upon different immune challenges, whereas overexpression of this miRNA family led to reduced TFH cell responses. Mechanistically, miR-23~27~24 clusters coordinately control TFH cells through targeting a network of genes that are crucial for TFH cell biology. Among them, thymocyte selection-associated HMG-box protein (TOX) was identified as a central transcription regulator in TFH cell development. TOX is highly up-regulated in both mouse and human TFH cells in a BCL6-dependent manner. In turn, TOX promotes the expression of multiple molecules that play critical roles in TFH cell differentiation and function. Collectively, our results establish a key miRNA regulon that maintains optimal TFH cell responses for resultant humoral immunity.

Published
2019

46. Bandgap expansion and dielectric suppression of self-assembled Ge nanocrystals.

Author

Goh, Eunice S. M., Chen, T. P., Huang, S. F., Liu, Y. C., and Sun, C. Q.

Subjects
GERMANIUM, NANOCRYSTALS, OPTICAL properties, DIELECTRICS, QUANTUM theory
Abstract

The bandgap and optical properties (dielectric functions and optical constants) of dome-shaped Ge nanocrystals (nc-Ge) with average sizes of ∼6 nm in height and ∼13 nm in diameter have been investigated using spectroscopic ellipsometry based on the Forouhi-Bloomer optical dispersion model. As compared to bulk crystalline Ge, the nc-Ge exhibited a bandgap expansion of ∼0.2 eV and a significant reduction in the dielectric function. The bandgap expansion and dielectric suppression are discussed in terms of the quantum confinement effect as well as the bond contraction model. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results